Sign In
Buy IONS
$73.82
+0.85 (+1.16%)
At Close: Jun 03, 2026
Ionis announces changes to its board of directors at annual meeting of stockholders
07:59pm, Wednesday, 02'nd Jun 2021
CARLSBAD, Calif., June 2, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced changes to its board of directors.
Ionis: Price Slump Is An Opportunity To Buy The Pipeline
03:04am, Wednesday, 02'nd Jun 2021
Ionis slumped following cancellation of 2 pipeline programs. There are numerous clinical stage programs that are ongoing.
The Best Biotech Stocks to Buy With $500
06:01am, Monday, 31'st May 2021
A modest amount goes a long way when you invest in biotech stocks.
Ionis to present at upcoming investor conferences
07:05am, Wednesday, 26'th May 2021
CARLSBAD, Calif., May 26, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will present a company overview at the following virtual investor conferences
Ionis (IONS) Q1 Loss Widens Year Over Year, Sales Miss
10:31am, Thursday, 06'th May 2021
Ionis (IONS) Q1 adjusted loss per share was wider than the year-ago figure. The company maintains its guidance for 2021.
Ionis to present at upcoming investor conferences
07:05am, Thursday, 06'th May 2021
CARLSBAD, Calif., May 6, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in virtual fireside chats at the following investor conferenc
Ionis Pharmaceuticals, Inc. (IONS) CEO Brett Monia on Q1 2021 Results - Earnings Call Transcript
06:51pm, Wednesday, 05'th May 2021
Ionis Pharmaceuticals, Inc. (IONS) CEO Brett Monia on Q1 2021 Results - Earnings Call Transcript
Ionis Pharmaceuticals (IONS) Reports Q1 Loss, Lags Revenue Estimates
09:24am, Wednesday, 05'th May 2021
Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of -33.33% and -16.06%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock
Ionis reports first quarter 2021 financial results and recent business achievements
07:00am, Wednesday, 05'th May 2021
CARLSBAD, Calif., May 5, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today reported its financial results for the first quarter of 2021 and recent business highlights.
Ionis to hold first quarter 2021 financial results webcast
07:05am, Wednesday, 21'st Apr 2021
CARLSBAD, Calif., April 21, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Wednesday, May 5 th at 11:30 a.m.
Ionis initiates pivotal clinical study of novel antisense medicine to treat patients with Alexander disease
07:05am, Tuesday, 20'th Apr 2021
CARLSBAD, Calif., April 20, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced it has initiated a pivotal clinical study of ION373 in patients with Alexander disease, a
Ionis prices private placement of convertible senior notes
07:05am, Thursday, 08'th Apr 2021
CARLSBAD, Calif., April 8, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today the pricing of $550.0 million aggregate principal amount of 0% Convertible Senior Notes due
Ionis Axes Akcea's 70% Workforce Under Restructuring Plan
07:15am, Wednesday, 07'th Apr 2021
Ionis Pharmaceuticals Inc (NASDAQ: IONS) said it expanded its distribution agreement with Swedish Orphan Biovitrum AB (“Sobi”) for Tegsedi in North America. Tegsedi is indicated for polyneuropat
Ionis announces proposed private placement of convertible notes
04:36pm, Tuesday, 06'th Apr 2021
CARLSBAD, Calif., April 6, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it intends to offer, subject to market conditions and other factors, $500.0 million agg
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS
02:10am, Tuesday, 06'th Apr 2021
NEW YORK, April 6, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Ionis Pharmaceuticals, Inc. ("Ionis" or the "Company") (NASDAQ: IONS). Such investors are ad
